2024年7月19日 · Dolutegravir is an antiviral medicine that is used with other medications to treat HIV, the virus that can cause the acquired immunodeficiency syndrome (AIDS). Dolutegravir is not a cure for HIV or AIDS. Dolutegravir is for use in adults and children as young as 4 weeks old and weighing at least 6 pounds (3 kilograms).

2024年6月27日 · [Dovato] DTG/Lamivudine (3TC) Adolescents Aged ≥12 Years and Weighing ≥25 kg and Adult Dose. One tablet once daily with or without food as a complete regimen in antiretroviral (ARV)-naive adults with no known mutations associated with resistance to the individual components of Dovato [Juluca] DTG/Rilpivirine. Adult Dose

Dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. [1] . It is a combination of dolutegravir, lamivudine, and tenofovir disoproxil. [1] .

Dolutegravir (DTG), sold under the brand name Tivicay, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. [6] . It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure. [7] …

Depending on the efficacy and tolerance of dolutegravir. Administer with caution to patients with severe hepatic impairment or coinfection with hepatitis B or hepatitis C virus. rarely: hepatotoxicity, hypersensitivity reactions.

2024年7月29日 · This drug plus (emtricitabine-tenofovir disoproxil fumarate [DF] or lamivudine/zidovudine) is recommended as a preferred regimen for nonoccupational postexposure prophylaxis of HIV infection. This drug should not be used in pregnant women early in pregnancy as the risk of an unborn infant developing a …

2024年3月6日 · Dolutegravir (brand names: Tivicay and Tivicay PD) is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in combination with:

Dolutegravir is in a class of medications called HIV integrase inhibitors. It works by decreasing the amount of HIV in your blood and increasing the number of immune cells that help fight infections in your body.

In April 2019, the U.S. Food and Drug Administration approved a combination pill comprising the integrase inhibitor dolutegravir (DTG), 50 mg, and the NRTI lamivudine (3TC), 300 mg, for use as a complete ARV regimen for initial HIV treatment of patients.

2024年12月4日 · Patients with documented or suspected resistance to integrase inhibitors : 1 tablet of 50 mg BID with or without food. The recommended daily dose of dispersible tablets for adults is 30 mg (6 tablets of 5 mg).